An Open Label Study to Evaluate the Pharmacokinetics of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 mcg) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2016
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 30 Nov 2016 Status changed from active, no longer recruiting to completed.
- 14 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 19 Sep 2016 Status changed from not yet recruiting to recruiting.